{"status": "Ok", "redirect_url": "https://www.businesswire.com/news/home/20260618308888/en/Incyte-Japan-Announces-Approval-of-Minjuvi%C2%AE-tafasitamab-in-Combination-with-Lenalidomide-for-the-Treatment-of-Adults-with-Relapsed-or-Refractory-Diffuse-Large-B-Cell-Lymphoma-DLBCL", "message": "News view counter 808323 successfully enlarged"}